GlycoMimetics Company Profile (NASDAQ:GLYC)

About GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics logoGlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GLYC
  • CUSIP: N/A
  • Web: www.glycomimetics.com
Capitalization:
  • Market Cap: $342.94 million
  • Outstanding Shares: 32,723,000
Average Prices:
  • 50 Day Moving Avg: $11.25
  • 200 Day Moving Avg: $8.32
  • 52 Week Range: $3.82 - $16.94
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.05
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $18,500.00
  • Price / Sales: 18,537.14
  • Book Value: $3.53 per share
  • Price / Book: 2.97
Profitability:
  • EBIDTA: ($32,240,000.00)
  • Return on Equity: -57.51%
  • Return on Assets: -51.78%
Debt:
  • Current Ratio: 21.99%
  • Quick Ratio: 21.99%
Misc:
  • Average Volume: 2.69 million shs.
  • Beta: 3.23
  • Short Ratio: 10.99
 

Frequently Asked Questions for GlycoMimetics (NASDAQ:GLYC)

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.07. View GlycoMimetics' Earnings History.

Where is GlycoMimetics' stock going? Where will GlycoMimetics' stock price be in 2017?

5 brokerages have issued 12-month price targets for GlycoMimetics' shares. Their predictions range from $9.00 to $21.00. On average, they expect GlycoMimetics' share price to reach $14.75 in the next year. View Analyst Ratings for GlycoMimetics.

What are analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:

  • 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (8/7/2017)
  • 2. Cowen and Company analysts commented, "GLYC’s GMI-1271, an E-selectin antagonist, in a Ph1/2 AML trial, has generated very." (5/9/2017)

Who are some of GlycoMimetics' key competitors?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:

  • M. James E. Barrett Ph.D., Chairman of the Board
  • Rachel K. King, President, Chief Executive Officer, Founder, Director
  • Brian Hahn, Chief Financial Officer
  • John Magnani Ph.D., Chief Scientific Officer, Vice President - Research, Director
  • Helen M. Thackray M.D., Vice President - Clinical Development, Chief Medical Officer
  • Patricia S. Andrews, Director
  • Mark Alan Goldberg M.D., Director
  • Daniel M. Junius, Director
  • Scott Koenig M.D., Ph.D., Director
  • Timothy R. Pearson, Director

Who owns GlycoMimetics stock?

GlycoMimetics' stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (34.84%), Franklin Resources Inc. (7.54%), Jennison Associates LLC (6.47%), FMR LLC (6.10%), Vanguard Group Inc. (3.43%) and Redmile Group LLC (1.83%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and Mark Alan Goldberg. View Institutional Ownership Trends for GlycoMimetics.

Who sold GlycoMimetics stock? Who is selling GlycoMimetics stock?

GlycoMimetics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., State Street Corp, Northern Trust Corp and Nationwide Fund Advisors. View Insider Buying and Selling for GlycoMimetics.

Who bought GlycoMimetics stock? Who is buying GlycoMimetics stock?

GlycoMimetics' stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Franklin Resources Inc., Redmile Group LLC, Janus Henderson Group PLC, Vanguard Group Inc., EAM Investors LLC and Broadfin Capital LLC. Company insiders that have bought GlycoMimetics stock in the last two years include Daniel M Junius and Mark Alan Goldberg. View Insider Buying and Selling for GlycoMimetics.

How do I buy GlycoMimetics stock?

Shares of GlycoMimetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GlycoMimetics stock can currently be purchased for approximately $10.48.


MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GlycoMimetics (NASDAQ:GLYC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.75 (40.74% upside)

Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/7/2017SunTrust Banks, Inc.Set Price TargetBuy$21.00LowView Rating Details
8/4/2017Stifel NicolausReiterated RatingBuy$13.00 -> $17.00LowView Rating Details
6/6/2017Jefferies Group LLCLower Price TargetBuy$16.00 -> $9.00HighView Rating Details
5/28/2017Cowen and CompanyReiterated RatingOutperformLowView Rating Details
5/19/2017Canaccord GenuityReiterated RatingBuy$12.00HighView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for GlycoMimetics (NASDAQ:GLYC)
Earnings by Quarter for GlycoMimetics (NASDAQ:GLYC)
Earnings History by Quarter for GlycoMimetics (NASDAQ GLYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.37)($0.30)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.37)($0.34)ViewN/AView Earnings Details
3/1/2017Q4 2016($0.35)($0.36)$4.50 millionViewN/AView Earnings Details
11/4/2016Q216($0.44)($0.34)$0.02 millionViewN/AView Earnings Details
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details
11/12/2015Q3($0.40)($0.38)$2.10 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.40)$0.51$20.04 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.22)($0.39)ViewN/AView Earnings Details
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details
7/31/2014Q2 2014$0.24$0.39$9.08 million$15.03 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.30)ViewN/AView Earnings Details
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)
2017 EPS Consensus Estimate: ($1.42)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.38)($0.37)($0.38)
Q2 20172($0.40)($0.30)($0.35)
Q3 20172($0.43)($0.25)($0.34)
Q4 20172($0.44)($0.26)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for GlycoMimetics (NASDAQ:GLYC)
Insider Ownership Percentage: 43.80%
Institutional Ownership Percentage: 63.69%
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)
Institutional Ownership by Quarter for GlycoMimetics (NASDAQ:GLYC)
Insider Trades by Quarter for GlycoMimetics (NASDAQ:GLYC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017Helen M ThackraySVPSell2,000$15.57$31,140.00View SEC Filing  
5/19/2017Helen M ThackraySVPSell2,000$12.14$24,280.00View SEC Filing  
12/20/2016Daniel M. JuniusDirectorBuy5,000$6.01$30,050.00View SEC Filing  
10/3/2016Helen M ThackrayVPSell4,000$7.00$28,000.00View SEC Filing  
7/20/2016Helen M ThackrayVPSell2,000$8.00$16,000.00View SEC Filing  
7/6/2016Helen M ThackrayCMOSell22,000$7.00$154,000.00View SEC Filing  
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.69View SEC Filing  
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for GlycoMimetics (NASDAQ:GLYC)
Latest Headlines for GlycoMimetics (NASDAQ:GLYC)
Source:
DateHeadline
americanbankingnews.com logoQ3 2017 Earnings Forecast for GlycoMimetics, Inc. (NASDAQ:GLYC) Issued By SunTrust Banks
www.americanbankingnews.com - August 9 at 8:08 AM
finance.yahoo.com logoGlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 8, 2017
finance.yahoo.com - August 8 at 6:48 PM
americanbankingnews.com logoGlycoMimetics, Inc. (GLYC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - August 8 at 12:34 AM
americanbankingnews.com logoGlycoMimetics, Inc. (GLYC) Posts Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - August 5 at 9:56 PM
americanbankingnews.com logoGlycoMimetics, Inc. (NASDAQ:GLYC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 8:56 PM
americanbankingnews.com logo Brokerages Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.37 EPS
www.americanbankingnews.com - August 5 at 12:44 PM
americanbankingnews.com logoStifel Nicolaus Reiterates Buy Rating for GlycoMimetics, Inc. (NASDAQ:GLYC)
www.americanbankingnews.com - August 5 at 11:34 AM
finance.yahoo.com logoGlycoMimetics, Inc. – Value Analysis (NASDAQ:GLYC) : August 1, 2017
finance.yahoo.com - August 1 at 7:41 PM
americanbankingnews.com logoGlycoMimetics, Inc. (GLYC) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 20 at 10:46 PM
finance.yahoo.com logoGlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017
finance.yahoo.com - July 19 at 7:45 PM
americanbankingnews.com logoGlycoMimetics, Inc. (NASDAQ:GLYC) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - July 18 at 11:32 PM
americanbankingnews.com logoZacks: Analysts Expect GlycoMimetics, Inc. (NASDAQ:GLYC) to Announce -$0.38 EPS
www.americanbankingnews.com - July 14 at 11:14 AM
americanbankingnews.com logoGlycoMimetics, Inc. (NASDAQ:GLYC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 11 at 8:50 PM
247wallst.com logoFDA Issues an Approval Not Seen in Almost 20 Years
247wallst.com - July 8 at 11:07 AM
reuters.com logoBRIEF-GlycoMimetics Inc says to receive European patent for GMI-1271
www.reuters.com - July 6 at 8:59 PM
finance.yahoo.com logoGlycoMimetics to Receive European Patent for GMI-1271
finance.yahoo.com - July 6 at 8:59 PM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock?
finance.yahoo.com - June 30 at 3:22 PM
americanbankingnews.com logoZacks: Brokerages Expect GlycoMimetics, Inc. (GLYC) to Announce -$0.38 Earnings Per Share
www.americanbankingnews.com - June 20 at 8:18 AM
americanbankingnews.com logoGlycoMimetics, Inc. (GLYC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 16 at 6:32 PM
finance.yahoo.com logoGlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors
finance.yahoo.com - June 12 at 6:16 PM
americanbankingnews.com logoShort Interest in GlycoMimetics Inc (GLYC) Rises By 248.2%
www.americanbankingnews.com - June 11 at 7:24 AM
americanbankingnews.com logoFY2017 EPS Estimates for GlycoMimetics Inc (GLYC) Boosted by Analyst
www.americanbankingnews.com - June 8 at 8:26 AM
finance.yahoo.com logoToday's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics
finance.yahoo.com - June 7 at 10:52 AM
americanbankingnews.com logoGlycoMimetics' (GLYC) Buy Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - June 6 at 11:38 PM
americanbankingnews.com logoGlycoMimetics Inc (GLYC) Price Target Raised to $16.00
www.americanbankingnews.com - June 6 at 9:18 AM
reuters.com logoBRIEF-Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO
www.reuters.com - June 5 at 5:35 PM
finance.yahoo.com logoGlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 5:35 PM
finance.yahoo.com logoGlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting
finance.yahoo.com - June 5 at 10:53 AM
americanbankingnews.com logoGlycoMimetics Inc (GLYC) Upgraded at ValuEngine
www.americanbankingnews.com - June 4 at 2:32 PM
rttnews.com logoALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD
www.rttnews.com - May 31 at 9:02 AM
finance.yahoo.com logoGlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271
finance.yahoo.com - May 31 at 9:02 AM
americanbankingnews.com logoHelen M. Thackray Sells 2,000 Shares of GlycoMimetics Inc (GLYC) Stock
www.americanbankingnews.com - May 30 at 8:31 PM
finance.yahoo.com logoGlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 30 at 5:22 PM
americanbankingnews.com logoCowen and Company Reaffirms Outperform Rating for GlycoMimetics Inc (GLYC)
www.americanbankingnews.com - May 28 at 9:34 AM
streetinsider.com logoGlycoMimetics (GLYC) Says GMI-1271 Received EU Orphan Drug Designation for AML
www.streetinsider.com - May 25 at 7:52 PM
reuters.com logoBRIEF-Glycomimetics Inc terminates sales agreement with Cowen and Company
www.reuters.com - May 25 at 7:52 PM
finance.yahoo.com logoGlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia
finance.yahoo.com - May 25 at 7:52 PM
finance.yahoo.com logoHere's Why GlycoMimetics Rose as Much as 21% Today
finance.yahoo.com - May 25 at 7:52 PM
finance.yahoo.com logoGlycoMimetics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - May 24 at 11:56 AM
streetinsider.com logoGlycoMimetics (GLYC) Plans 6M Share Common Stock Offering
www.streetinsider.com - May 23 at 5:07 PM
rttnews.com logoGlycoMimetics Inc. (GLYC) Is Down Following Offering Announcement
www.rttnews.com - May 23 at 5:07 PM
finance.yahoo.com logoShark Bites: There Wasn't Even a Dip to Buy
finance.yahoo.com - May 23 at 11:44 AM
americanbankingnews.com logoGlycoMimetics Inc (GLYC) SVP Helen M. Thackray Sells 2,000 Shares
www.americanbankingnews.com - May 22 at 10:28 PM
americanbankingnews.com logoGlycoMimetics Inc (GLYC) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 22 at 6:20 PM
finance.yahoo.com logoGlycoMimetics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 22 at 5:02 PM
nasdaq.com logoHere's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today
www.nasdaq.com - May 19 at 10:16 PM
americanbankingnews.com logoGlycoMimetics Inc (GLYC) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - May 19 at 9:36 PM
finance.yahoo.com logoWhy GlycoMimetics Is Ripping 19% Higher Today
finance.yahoo.com - May 19 at 5:15 PM
finance.yahoo.com logoETFs with exposure to GlycoMimetics, Inc. : May 19, 2017
finance.yahoo.com - May 19 at 5:15 PM
rttnews.com logoGlycoMimetics Inc. (GLYC) Soared To A New High On FDA Breakthrough Designation
www.rttnews.com - May 19 at 8:36 AM

Social

Chart

GlycoMimetics (GLYC) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff